Cargando…

An In Vivo Microdialysis Study of FLZ Penetration through the Blood-Brain Barrier in Normal and 6-Hydroxydopamine Induced Parkinson's Disease Model Rats

FLZ (N-[2-(4-hydroxy-phenyl)-ethyl]-2-(2,5-dimethoxy-phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide) is a novel synthetic squamosamide derivative and a potential anti-Parkinson's disease (PD) agent. The objective of the present study was to investigate the penetration of free FLZ across the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Jinfeng, Liu, Qian, Li, Yingfei, Sun, Hua, Zhang, Jinlan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090575/ https://www.ncbi.nlm.nih.gov/pubmed/25045708 http://dx.doi.org/10.1155/2014/850493

Ejemplares similares

P-Glycoprotein Mediated Efflux Limits the Transport of the Novel Anti-Parkinson's Disease Candidate Drug FLZ across the Physiological and PD Pathological In Vitro BBB Models
por: Liu, Qian, et al.
Publicado: (2014)

Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment
por: Shang, Junmei, et al.
Publicado: (2021)

Dexamethasone-Enhanced Microdialysis and Penetration Injury
por: Jaquins-Gerstl, Andrea, et al.
Publicado: (2020)

Genome-wide Identification and Characterization of FCS-Like Zinc Finger (FLZ) Family Genes in Maize (Zea mays) and Functional Analysis of ZmFLZ25 in Plant Abscisic Acid Response
por: Chen, Shunquan, et al.
Publicado: (2021)

Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis
por: Dorn, Christoph, et al.
Publicado: (2022)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease In Vitro and In Vivo
por: Zhou, Hefeng, et al.
Publicado: (2019)

Microdialysis on Ex Vivo Porcine Ear Skin Can Validly Study Dermal Penetration including the Fraction of Transfollicular Penetration—Demonstrated on Caffeine Nanocrystals
por: Klein, Anna Lena, et al.
Publicado: (2021)

Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis
por: Gill, Christian M, et al.
Publicado: (2022)

Human Albumin Prevents 6-Hydroxydopamine-Induced Loss of Tyrosine Hydroxylase in In Vitro and In Vivo
por: Zhang, Li-Juan, et al.
Publicado: (2012)

Squamosamide Derivative FLZ Protects Pancreatic β-Cells from Glucotoxicity by Stimulating Akt-FOXO1 Pathway
por: Kong, Xiangchen, et al.
Publicado: (2015)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Squamosamide Derivative FLZ Diminishes Aberrant Mitochondrial Fission by Inhibiting Dynamin-Related Protein 1
por: Yang, Hanyu, et al.
Publicado: (2021)

4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson's Disease
por: Hu, Jing, et al.
Publicado: (2017)

Pharmacokinetics of BPA in Gliomas with Ultrasound Induced Blood-Brain Barrier Disruption as Measured by Microdialysis
por: Yang, Feng-Yi, et al.
Publicado: (2014)

Microdialysis in awake macaque monkeys for central nervous system pharmacokinetics
por: Thiollier, Thibaud, et al.
Publicado: (2018)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson’s disease via inhibiting oxidative stress
por: Nourmohammadi, Saeideh, et al.
Publicado: (2022)

Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity
por: Zhang, Dan, et al.
Publicado: (2008)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
por: Liu, Lan-Xiang, et al.
Publicado: (2018)

Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson’s disease
por: Gramage, Esther, et al.
Publicado: (2022)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo
por: Stalmans, Sofie, et al.
Publicado: (2015)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Simultaneous blood and brain microdialysis in a free-moving mouse to test blood-brain barrier permeability of chemicals
por: Umezu, Toyoshi, et al.
Publicado: (2020)

Microdialysis SPR: diffusion-gated sensing in blood
por: Breault-Turcot, Julien, et al.
Publicado: (2015)

FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation
por: Bao, Xiu-Qi, et al.
Publicado: (2013)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
por: Haas, Stefan Jean-Pierre, et al.
Publicado: (2016)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9eqnpbauvnnd3tejgedbnaughg